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Summary 22 
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the primary pathogen of enzootic 23 
pneumonia, a chronic respiratory disease in pigs. Infections occur worldwide and cause major 24 
economic losses to the pig industry. The present paper reviews the current knowledge on M. 25 
hyopneumoniae infections, with emphasis on identification and analysis of knowledge gaps for 26 
optimizing control of the disease. Close contact between infected and susceptible pigs is the 27 
main route of M. hyopneumoniae transmission. Management and housing conditions 28 
predisposing for infection or disease are known, but further research is needed to better 29 
understand M. hyopneumoniae transmission patterns in modern pig production systems, and to 30 
assess the importance of the breeding population for downstream disease control. The organism 31 
is primarily found on the mucosal surface of the trachea, bronchi, and bronchioles. Different 32 
adhesins and lipoproteins are involved in the adherence process. However, a clear picture of 33 
the virulence and pathogenicity of M. hyopneumoniae is still missing. The role of glycerol 34 
metabolism, myo-inositol metabolism and the Mycoplasma Ig binding protein (MIB) - 35 
Mycoplasma Ig protease (MIP) system should be further investigated for their contribution to 36 
virulence. The destruction of the mucociliary apparatus, together with modulating the immune 37 
response, enhances the susceptibility of infected pigs to secondary pathogens. Clinical signs 38 
and severity of lesions depend on different factors, such as management, environmental 39 
conditions and likely also M. hyopneumoniae strain. The potential impact of strain variability 40 
on disease severity is not well defined. Diagnostics could be improved by developing tests that 41 
may detect virulent strains, by improving sampling in live animals and by designing ELISA 42 
assays allowing discrimination between infected and vaccinated pigs. The currently available 43 
vaccines are often cost-efficient, but the ongoing research on developing new vaccines that 44 
confer protective immunity and reduce transmission should be continued, as well as 45 
optimization of protocols to eliminate M. hyopneumoniae from pig herds. 46 
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Introduction 48 
Mycoplasma hyopneumoniae (M. hyopneumoniae) is the primary pathogen of enzootic 49 
pneumonia (EP), a chronic respiratory disease in pigs, and one of the primary agents involved 50 
in the porcine respiratory disease complex (PRDC; Thacker and Minion, 2012). Infections with 51 
M. hyopneumoniae are highly prevalent worldwide, and cause tremendous financial losses to 52 
the pig industry. Losses are mainly due to costs for treatment and vaccination, decreased 53 
performance and increased mortality derived from secondary infections (Holst et al., 2015).  54 
Similar to other Mycoplasmas, M. hyopneumoniae has a small genome, lacks a cell wall and is 55 
pleomorphic. M. hyopneumoniae is very difficult to isolate because of its slow growth and 56 
potential overgrowth with other swine mycoplasmas. Bacterial culture is usually attempted 57 
when an isolate is deemed, but not for routine diagnostics. The organism is primarily identified 58 
on the mucosal surface of the trachea, bronchi, and bronchioles (Blanchard et al., 1992). It 59 
affects the mucosal clearance system by disrupting the cilia on the epithelial surface and, 60 
additionally, the organism modulates the immune system of the respiratory tract (Thacker and 61 
Minion, 2012). Therefore, M. hyopneumoniae predisposes animals to concurrent infections 62 
with other respiratory pathogens including bacteria, parasites and viruses. Infections also lead 63 
to increased use of antimicrobials. While M. hyopneumoniae can be virtually recovered from 64 
pigs of all sites in segregated production systems, the clinical presentation of EP is mainly 65 
observed in growing and finishing pigs. Vaccination against M. hyopneumoniae is widely 66 
practiced and is often cost-efficient in affected herds. Additional control measures include 67 
optimizing management and biosecurity, reducing other risk factors and disease elimination. 68 
The present paper reviews the current knowledge on M. hyopneumoniae infections, with 69 
emphasis on identification and analysis of knowledge gaps for optimizing control measures. 70 
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Epidemiology 71 
To date, domestic pigs and wild boar are the only hosts known to become infected with M. 72 
hyopneumoniae. In pigs, there is no clear indication of susceptibility based on age, although 73 
clinical presentation of the disease is usually evident in grow-finishing stages. Close contact 74 
between infected and susceptible pigs is the main route of M. hyopneumoniae transmission. 75 
Piglets are considered free from M. hyopneumoniae at birth, as in utero transmission has not 76 
been documented, and first exposure events occur during the lactation period, when piglets are 77 
in contact with dams shedding the microorganism (Calsamiglia and Pijoan, 2000; Nathues et 78 
al., 2013). In fact, the length of the lactation period has been suggested as one risk factor for 79 
piglet colonization with M. hyopneumoniae prior to weaning (Pieters et al., 2014).  80 
Piglet colonization with M. hyopneumoniae at weaning age is of special importance in 81 
segregated production systems, where pigs are transferred to clean facilities for the growing 82 
and finishing phases. It has been proposed that the initial group colonization with M. 83 
hyopneumoniae determines downstream clinical presentation and disease severity (Fano et al., 84 
2007; Sibila et al., 2007), although the effect of other factors needs to be considered for disease 85 
presentation as well. The influence of the lactation period duration in piglet colonization is 86 
evidenced by the successful application of segregated early weaning (SEW) to obtain M. 87 
hyopneumoniae-free pigs born to positive dams (Alexander et al., 1980). Research data has 88 
shown that transmission of M. hyopneumoniae among pen-mates is slow (Meyns et al., 2004; 89 
Villarreal et al., 2011b; Roos et al., 2016), fitting the picture that disease presentation can be 90 
the result of early group colonization and subsequent transmission events. However, a clear 91 
understanding of M. hyopneumoniae transmission in the field is still needed in order to improve 92 
infection models used in experimental research.  93 
Dams and piglets in the breeding herds are considered the reservoir of M. hyopneumoniae 94 
infections for the entire production system. Circulation of M. hyopneumoniae is thought to 95 
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occur among existing sows and be transmitted to incoming gilts, which are capable of 96 
maintaining the pathogen within the farm and are responsible for the majority of bacterial 97 
shedding to newborn pigs (Calsamiglia and Pijoan, 2000; Fano et al., 2005). In this manner, the 98 
constant addition of gilts and birth of piglets provide critical susceptible populations needed to 99 
maintain pathogen transmission. On the other hand, infection with M. hyopneumoniae has a 100 
long duration, reaching up to 240 days (Pieters et al., 2009), complicating the already slow 101 
disease transmission scenario observed in sow herds. A critical aspect of the epidemiology of 102 
M. hyopneumoniae is based on the long pathogen persistence, which determining factors are 103 
poorly understood. Nevertheless, management practices at the sow farm such as 104 
minimizing cross-fostering and limiting the length of the lactation period may help mitigating 105 
the effect of M. hyopneumoniae transmission by decreasing risk factors for piglet colonization 106 
(Nathues et al., 2013a; Nathues et al., 2013b; Pieters et al., 2014; Vangroenweghe et al., 2015). 107 
Therefore, identification of risk factors for disease transmission at the sow farm is key for 108 
downstream disease control. In continuous flow production systems, M. hyopneumoniae 109 
colonization in piglets at weaning may not be as influential as in segregated systems. In 110 
continuous flow systems, there is a fairly constant contact between animals of different ages, 111 
facilitating transmission of M. hyopneumoniae. In this respect, the colonization of piglets at 112 
weaning is not the only determining factor for downstream infection.  113 
An additional source of variability regarding epidemiology of M. hyopneumoniae lies on the 114 
demonstration of distinct strains circulating in the field. Partial sequencing of the P146 gene 115 
(Mayor et al., 2007), and Multiple-Locus Variable number tandem repeat Analysis (MLVA; 116 
Vranckx et al., 2011; Dos Santos et al., 2015) are commonly used to discriminate M. 117 
hyopneumoniae. The use of M. hyopneumoniae molecular characterization has aided outbreak 118 
and area spread investigations, by tracking specific strains. In addition, it has enabled research 119 
directed at understanding pathogen variability and its relationship with disease presentation 120 
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(Michiels et al., 2017). However, current tools for M. hyopneumoniae characterization are based 121 
on the sole evaluation of similarities in specific loci, and do not indicate strain virulence and/or 122 
antigenicity. Development of molecular characterization methods allowing strain virulence 123 
evaluation would be beneficial in order to tailor control strategies at the farm level, and could 124 
shed light on understanding potential cross-protection among strains.  125 
Vectors do not seem to play an important role in the transmission of M. hyopneumoniae in pigs, 126 
however, little research has been performed on this topic. Data from Nathues et al. (2012) 127 
showed that personnel working with pigs for several hours could harbor the bacterium in their 128 
upper respiratory tract, as detected via PCR in nasal swabs; however, the potential for pathogen 129 
transmission was not evaluated. Airborne transmission of M. hyopneumoniae has been 130 
suspected for decades (Goodwin, 1985). Cardona et al. (2005) demonstrated that the 131 
microorganism could travel for at least 300 m, and Otake at al. (2010) showed that air samples 132 
recovered M. hyopneumoniae  DNA from as far as 9.2 km from an infected farm. In the latter 133 
case, the air sample was shown to be infectious when inoculated to animals using a swine 134 
bioassay. 135 
The geographical distribution of M. hyopneumoniae infections is assumed to be worldwide. The 136 
prevalence is low in some Scandinavian countries, and Switzerland is free after the application 137 
of a national eradication program (Stark et al., 2007). Specific data on M. hyopneumoniae 138 
prevalence by country is not available in the literature, as the disease is not considered of 139 
obligatory report and does not limit commercial trade. 140 
Wild-boar has been shown to harbor M. hyopneumoniae and may carry identical genotypes 141 
found in EP outbreaks (Sibila et al., 2010; Kuhnert et al 2014). However, this might be rather 142 
the result of spillover from domestic pig outbreaks than representing wild boars as a reservoir. 143 
  144 
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Incubation period and kinetic pattern 145 
Under experimental conditions, where usually seronegative animals are challenged with a high 146 
infectious dose of M. hyopneumoniae, lung lesions and onset of coughing can appear as early 147 
as 7-14 days post-infection (dpi; Blanchard et al., 1992; Lorenzo et al, 2006), with maximum 148 
severity and extension of lung lesions occurring around 28 dpi (Villarreal et al., 2011a). The 149 
minimal infectious dose to induce lung lesions was established at 105 color-changing units per 150 
ml (CCU/ml) per pig (corresponding to 108 mycoplasmas; Marois et al., 2010). Since 151 
differences in virulence among strains do exist, this minimal infectious dose is probably strain 152 
dependent.  153 
Under natural conditions, the incubation period is difficult to predict as it depends on production 154 
system, presence of secondary infections, immune status of animals, virulence of the M. 155 
hyopneumoniae strain and infectious pressure (Sibila et al., 2009). Indeed, it was postulated that 156 
a critical mass of pigs should be infected to elicit the appearance of clinical signs (Calsamiglia 157 
et al., 1999). Nevertheless, in clinically affected farms, seroconversion as well as coughing 158 
would appear after, approximately, 1 to 6 weeks post infection (Leon et al., 2001).  159 
M. hyopneumoniae is excreted from the respiratory tract of infected individuals through 160 
exhalation of microscopic droplets during coughing episodes and /or by nose-to-nose direct 161 
contact (Hermann et al., 2008). M. hyopneumoniae DNA has also been detected in different 162 
samples from the oral cavity such as oro-parhyngeal swabs (Hermann et al., 2008; Fablet et al., 163 
2010), oral fluids (Roos et al., 2016) and tonsilar samples (Sibila et al., 2007, Fablet et al., 164 
2010). 165 
It is known that sows of different parity number may shed the organism, the younger ones being 166 
the main shedders (Sibila et al., 2007; Boonsoongnern et al., 2012). Practices directed at 167 
segregation of parity, giving special care to parity-one dams and piglets and separating them 168 
from the rest of the herd, have been reported to provide significant control of M. hyopneumoniae 169 
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infections in young parity dams (Moore, 2003). Nonetheless, it remains unclear whether this 170 
excretion is uniform and continuous or, on the contrary, is of variable intensity and intermittent. 171 
An experimental longitudinal study showed the onset of excretion at 7-14 dpi, followed by an 172 
irregular and inconsistent shedding (detection of M. hyopneumoniae DNA at nasal cavities) up 173 
to 91 dpi (Fano et al., 2005). Indeed, longer excretion was indirectly demonstrated by the 174 
transmissibility of M. hyopneumoniae to naïve contact pigs at 214 dpi (Pieters et al., 2009). 175 
Under natural conditions, shedding duration and kinetics are more difficult to be ascertained, 176 
since a low bacterial load is usually present at upper respiratory tract sites (Hermann et al.,2008; 177 
Sibila et al., 2009). In a study where M. hyopneumoniae detection was assessed in nasal swabs 178 
at 9 sampling points through the productive life of pigs, two out of 33 (6%) non-vaccinated 179 
animals were continuously nested PCR positive in the last five sampling points (from 12 to 25 180 
weeks of age; Sibila et al., 2007). On the contrary, in a longitudinal study in sows, only 2.4% 181 
of them had at least one of the three assessed respiratory sites (nasal, tonsillar and oro-182 
pharyngeal swabs) positive by PCR. For all these positive sows, M. hyopneumoniae was 183 
detected at one out of eight sampling occasions (Fablet et al., 2011). Takeuti et al. (2017) 184 
followed 44 gilts longitudinally from their weaning until after the weaning of their first 185 
offspring, collecting laryngeal swabs every 30 days in an endemically infected farm, and 186 
identified approximately 20% of gilts negative throughout the study, while other gilts were 187 
positive for M. hyopneumoniae by real-time mostly once, with a proportion of gilts being 188 
positive at multiple samplings. Therefore, considering that the sow population is the origin of 189 
M. hyopneumoniae circulation, shedding pattern in such population deserves further 190 
investigations. 191 
  192 
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Pathogenicity 193 
Adhesins and lipoproteins 194 
Adhesion along the entire length of cilia of ciliated epithelium of the respiratory tract (trachea, 195 
bronchi and bronchioles) of pigs is the first step of infection with M. hyopneumoniae followed 196 
by induction of ciliostasis and loss of cilia (Debey and Ross, 1994). The primary adhesin of M. 197 
hyopneumoniae is the P97 and its paralogues (Hsu et al. 1997; Hsu et al. 1998). The other family 198 
of adhesins, related with P97, is formed by P102 and its paralogues (Adams et al., 2005). 199 
Finally, P159 is an adhesin unrelated to the other two (Burnett et al., 2006). Adhesin receptors 200 
on the eukaryotic cell are mainly glycosaminoglycanes and fibronectin. Most of the proteins 201 
from the P97/P102 paralog families and P159 are post-translationally processed and cleaved, a 202 
system observed with many other surface-associated proteins (Seymour et al., 2010). Like that, 203 
Tacchi et al. (2016) identified 35 proteins that are endoproteolytically cleaved in M 204 
hyopneumoniae. These include not only adhesins but also lipoproteins and even multifunctional 205 
cytosolic proteins “moonlighting” at the cell surface. This massive processing and cleavage 206 
leads to a very dynamic surface topography of M. hyopneumoniae that could well be involved 207 
in host evasion and modulation of the immune response. The cleaved fragments of the P97/P102 208 
paralog families and P159 remain on the cell surface and function as receptors of heparin, 209 
plasminogen and fibronectin, thereby influencing interaction of M. hyopneumoniae with its host 210 
(Bogema et al., 2012, Simionatto et al., 2013).  211 
P146 (LppS) is an adhesion lipoprotein containing a serine rich region, the genetic basis of it is 212 
also used for genotyping (Mayor et al., 2007). The homolog in Mycoplasma conjunctivae was 213 
hypothesized to be involved in pathogenesis and in M. hyopneumoniae it is also proteolytically 214 
processed (Belloy et al., 2003, Bogema et al., 2012). This together with the fact that M. 215 
hyopneumoniae can alter the number of consecutive serine repeats in P146 (so far observed 216 
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from 9 up to 48) could indicate that it is also involved in antigen variation and immune evasion 217 
(Dos Santos et al. 2015).  218 
Cell-surface lipoproteins, alternatively called lipid associated membrane proteins (LAMP), 219 
have also been found to be implicated in apoptosis. Whole membrane lipoprotein fractions were 220 
shown to induce apoptosis via caspases 3 and 8 activation in vitro in various cell types, 221 
including porcine peripheral blood mononuclear cells (PBMC; Bai et al., 2015; Ni et al., 2015). 222 
Furthermore, LAMPs activate production of nitric oxide (NO) and reactive oxygen species 223 
(ROS) in the host cell. 224 
 225 
H2O2 production 226 
Mycoplasmas in general lack classical virulence factors like toxins. It has remained obscure for 227 
a long time how these smallest self-replicating organisms could elicit toxic effects. Recently 228 
the production of toxic metabolites like H2O2 was found as a virulence mechanism of certain 229 
mycoplasma species. The bovine pathogen Mycoplasma mycoides subsp. mycoides SC is able 230 
to take up glycerol efficiently, which is then metabolized by glycerolphosphate-oxidase (GlpO) 231 
leading to the production of hydrogen peroxide. Similar metabolic pathways account for 232 
virulence in the human pathogen Mycoplasma pneumoniae (Hames et al., 2009). For M. 233 
hyopneumoniae, Ferrarini et al. (2016) reconstructed a metabolic model based on its genome. 234 
They postulated an ability of M. hyopneumoniae to use glycerol as a carbon source, thereby 235 
enabling the production of hydrogen peroxide. In fact, the homologous gene glpD is present in 236 
M. hyopneumoniae. However, functional assays for testing production of hydrogen peroxide 237 
were so far all negative for various strains of M. hyopneumoniae (Kuhnert, personal 238 
communication). Thus, whether production of toxic metabolic compounds from glycerol is a 239 
possible virulence mechanism in M. hyopneumoniae remains to be investigated. 240 
 241 
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Comparative studies with other Mycoplasmas 242 
Differences in strain virulence have been observed for M. hyopneumoniae (Vicca et al., 2003; 243 
Villarreal et al., 2009; Woolley et al., 2012,). Moreover, the most closely related Mycoplasma 244 
flocculare is a commensal of the pig not causing any disease (Siqueira et al., 2013). This allows 245 
for large scale comparisons on the genome, transcriptome, proteome, metabolome and 246 
secretome level in order to find differences related to virulence and pathogenesis (Pinto et al., 247 
2009; Liu et al., 2013; Siqueira et al., 2013; Siqueira et al., 2014; Ferrarini et al., 2016; Paes et 248 
al., 2017). In a study comparing the pathogenic strain 168 with its attenuated derivative, Liu et 249 
al. (2013) found that besides the known virulence associated proteins (mainly adhesins), also 250 
mutations in genes involved in metabolism and growth contribute to virulence. In a genome-251 
reduced organism like M. hyopneumoniae that lost most of its biosynthetic capacity, it is not 252 
surprising that further loss of gene functions has a dramatic influence on survival and growth 253 
of the microorganism. This also holds true for e.g. lipoproteins involved in nutrient acquisition 254 
(Browning et al., 2011). Nevertheless, such attenuated strains could be a basis for live vaccines. 255 
A genome comparison of M. hyopneumoniae and M. flocculare revealed differences in genome 256 
structure and organization (Siqueira et al., 2013). Some genes of the P97 adhesin family were 257 
absent in M. flocculare, showed sequence differences or were missing domains involved in 258 
adhesion to host cells. However, there were no specific factors identified that could explain the 259 
pathogenic nature of M. hyopneumoniae compared to the commensal M. flocculare.  260 
An integrative conjugal element (ICE) has been identified in the genomes of pathogenic strains 261 
7448 and 232, while it is absent in the non-pathogenic strain J (Pinto et al., 2007). The ICE 262 
from M. hyopneumoniae, called ICEH, was also found in the pathogenic strain 168 but likewise 263 
in its attenuated variant (Liu et al., 2013). While ICE, acting as self-replicating mobile genetic 264 
elements, are generally recognized to be involved in virulence, their role in the pathogenicity 265 
of M. hyopneumoniae remains unclear. The fact that there are notable differences of ICEH 266 
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between the strains indicate that they are at least involved in horizontal gene transfer, thereby 267 
maintaining genome plasticity and variability of M. hyopneumoniae. 268 
Ferrarini et al. (2016) used a genome-scale metabolic modeling approach to get insight into the 269 
virulence of M. hyopneumoniae. Besides a glycerol conversion pathway potentially leading to 270 
peroxide production in M. hyopneumoniae, another significant metabolic pathway was 271 
identified to be absent in M. flocculare which is the myo-inositol uptake and catabolism. 272 
Functional and in vivo assays have to be conducted to proof whether these in silico findings 273 
play a role in virulence and pathogenicity.  274 
Differences in virulence could also be due to variation in expression levels of virulence 275 
associated genes like adhesins. This was observed in a proteome analysis of in vitro cultures 276 
comparing the non-pathogenic strain J to virulent strains 7448 and 7422 (Pinto et al., 2009). 277 
They identified 64 proteins being overexpressed in the pathogenic strains compared to the non-278 
pathogenic strain, the most prominent being P97.  279 
Finally, the secretomes of M. hyopneumoniae and M. flocculare grown in a serum reduced 280 
medium were compared recently, looking more precisely at factors directly involved in 281 
mycoplasma-host interaction (Paes et al., 2017). A higher number of secreted proteins was 282 
found with M. hyopneumoniae compared to M. flocculare (62 vs 26). While M. hyopneumoniae 283 
secreted adhesins, methylases, nucleases and lipoproteins, M. flocculare secreted only two 284 
adhesins that were also found in the M. hyopneumoniae secretome. There was a difference 285 
between the transcriptome and the secretome using the same Mycoplasma strains (Siqueira et 286 
al., 2014). 287 
These comparative “omics” studies confirmed that adhesins play a major role in virulence and 288 
pathogenesis. However, there are no clear-cut factors that differ between pathogenic and non-289 
pathogenic strains or differ between the pathogen M. hyopneumoniae and the commensal M. 290 
flocculare. 291 
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Mycoplasma-host interaction and immune modulation 292 
Infection with M. hyopneumoniae is often chronic what indicates a certain degree of immune 293 
evasion of the microbe. In a study looking at introgression of domestic swine genes into the 294 
wild boar population, an increased M. hyopneumoniae disease susceptibility in hybrid animals 295 
was observed (Goedbloed et al., 2015). The authors hypothesized that the large-scale use of 296 
antibiotics in the swine breeding sector may have led to selecting deleterious properties of 297 
domestic swine immune genes. These in turn lead to the increased disease susceptibility if 298 
introgression to the wild boar occurs. These observations confirm a certain host-predisposition 299 
for M. hyopneumoniae which in the opposite direction can also be achieved by selecting for 300 
more resistant breeds (Borjigin et al., 2016). Furthermore, it indicates certain “immune 301 
degeneration” of domestic pigs, allowing M. hyopneumoniae to cause disease in a well-302 
protected animal. The destruction of the mucociliary apparatus together with down-modulating 303 
the immune response at later stages enhances the susceptibility of M. hyopneumoniae infected 304 
pigs to secondary pathogens (Shen et al., 2017).  305 
The host immune response is considered to be the main driver of pulmonary lesions. At the 306 
same time, M. hyopneumoniae modulates the immune response in order to persist in the host. 307 
Pro-inflammatory cytokines like IL-1, TNF-α and IL-6 are induced during infection and 308 
plasmin is recognized as central to the regulation of inflammatory responses (Woolley et al., 309 
2013). A number of the P97/P102 adhesin family members interact with plasminogen of the 310 
porcine host and enhance its activation to plasmin, a serine protease which in turn stimulates 311 
macrophage signaling resulting in production of ROS and cytokine release, thereby 312 
contributing to inflammation (Syrovets et al., 2012). A leucine aminopeptidase has recently 313 
been shown to “moonlight” as a multifunctional adhesin, including binding and cleaving of 314 
plasminogen, on the M. hyopneumoniae cell surface (Jarocki et al., 2015). Plasminogen is 315 
readily available in the ciliated airways affected by M. hyopneumoniae (Seymour et al., 2012). 316 
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Interaction with surface accessible actin on the epithelial cells and causing cytoskeletal 317 
rearrangements allows the organism being phagocytosed. It is hypothesized that M. 318 
hyopneumoniae can survive within the phagolysosome, escape it and reside within the 319 
cytoplasm (Tacchi et al. 2016). Thereby it can not only evade the immune system but could 320 
disseminate to internal organs and persist within its host without causing disease. Isolation of 321 
M. hyopneumoniae from other tissue than lung has in fact been reported (Le Carrou et al., 2006; 322 
Marois et al., 2007; Marchioro et al., 2013).  323 
Immune evasion by specifically cleaving immunoglobulins has been described for M. mycoides 324 
subsp. capri (Arfi et al., 2016). This two-protein system consists of a Mycoplasma Ig binding 325 
protein (MIB) and a Mycoplasma Ig protease (MIP), where the MIB is necessary for the 326 
proteolytic activity of MIP. The two proteins are encoded by two genes organized in tandem 327 
and often found in multiple copies in various mycoplasmas including M. hyopneumoniae (Arfi 328 
et al., 2016). How far this MIB-MIP system plays a role in virulence and immune evasion of 329 
M. hyopneumoniae, deserves further studies.  330 
A clear picture of virulence and pathogenicity of M. hyopneumoniae is still not available The 331 
role of glycerol metabolism, myo-inositol metabolism and the MIB-MIP system should be 332 
further investigated for their contribution to virulence. 333 
 334 
Interaction of M. hyopneumoniae with other pathogens 335 
Different interactions have been described between M. hyopneumoniae and other pathogens. 336 
M. hyopneumoniae predisposes pigs to infections with secondary bacteria. Combined 337 
experimental infections with M. hyopneumoniae and either Pasteurella multocida (P. 338 
multocida) (Amass et al., 1994) or Actinobacillus pleuropneumoniae (A. pleuropneumoniae) 339 
(Marois et al., 2009) result in more severe lesions compared to the single infections. Co- or 340 
subsequent infections with P. multocida and A. pleuropneumoniae, and with other bacteria such 341 
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as Bordetella bronchiseptica, Haemophilus parasuis, Trueperella pyogenes, streptococci or 342 
staphylococci are commonly found in field outbreaks of EP. 343 
Initial studies focussing on the interaction between M. hyopneumoniae and porcine 344 
reproductive and respiratory syndrome virus (PRRSV) could not demonstrate a potentiating 345 
effect of both pathogens (Van Alstine et al., 1996). Subsequently, it was shown that M. 346 
hyopneumoniae significantly prolonged and increased the severity of PRRSV-induced 347 
pneumonia under experimental conditions (Thacker et al., 1999). Dual infection studies with 348 
M. hyopneumoniae and swine influenza virus (SIV) could not show the potentiating effects of 349 
both pathogens as observed with PRRSV. The effect was less pronounced and only transitory 350 
(Thacker et al. 2001; Yazawa et al. 2004). Deblanc et al. (2012) showed that M. hyopneumoniae 351 
infection increased the severity of H1N1 SIV but not that of H1N2 SIV. Opriessnig et al. (2004) 352 
indicated using an experimental study that M. hyopneumoniae infection potentiates the severity 353 
of porcine circovirus type 2 (PCV2)-associated lung and lymphoid lesions, increases the 354 
amount of PCV2-antigen and prolongs its presence, and increases the incidence of post-355 
weaning multisystemic wasting syndrome in pigs. Sibila et al. (2012) however, could not 356 
demonstrate an interaction between M. hyopneumoniae and PCV2 infection.  357 
Flesja and Ulvesaeter (1980) reported that the extent of pneumonia was associated with the 358 
presence of liver lesions due to migrating Ascaris suum larvae.  359 
Finally, Pósa et al. (2013) showed that pigs receiving feed contaminated with Fumonisin B 360 
elicited more severe lung lesions upon M. hyopneumoniae challenge infection compared to pigs 361 
fed with non-contaminated feed. Pigs that received feed contaminated with the mycotoxin 362 
deoxynivalenol (DON) did not develop more severe disease and lesions upon experimental M. 363 
hyopneumoniae infection than pigs fed with non-contaminated feed (Michiels et al., 2016). A 364 
full review of all interactions between different respiratory pathogens has been published by 365 
Opriessnig et al. (2011).  366 
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Clinical signs and lesions 367 
Infections with M. hyopneumoniae are clinically characterized by an intermittent, variable in 368 
intensity, dry non-productive cough (Sibila et al., 2009), which may last from weeks to months. 369 
When this type of coughing affects simultaneously many animals of different ages, also other 370 
pathogens such as SIV or PRRSV may be involved in the problem (Nathues et al., 2012). Under 371 
an endemic scenario, disease course implies high morbidity but low mortality. When M. 372 
hyopneumoniae enters into a naïve population, the disease may be more severe, affecting 373 
animals of all ages and increasing the morbidity up to 100% (Thacker and Minion, 2012). If 374 
other bacterial and/or viral agents are involved, or in case of poor air quality due to particulate 375 
matter and ammonia (Michiels et al., 2015), clinical signs may be aggravated including labored 376 
breathing, pyrexia, anorexia, lethargy and even death (Maes et al., 1996). In uncomplicated 377 
cases, a variable proportion of animals might remain subclinically infected for several weeks 378 
(Fano et al., 2005), with no evidence of coughing or pulmonary lesions at slaughter. 379 
Coughing is the direct consequence of the lung lesions observed in affected animals, which 380 
consist of purple to gray consolidated areas affecting the apical and middle lobes and, 381 
eventually, cranial part of diaphragmatic lobes (García-Morante et al., 2016). In case of 382 
secondary bacterial infections, pigs show heavier and firmer lungs with higher proportion of 383 
tissue affected, and gray-to-white mucopurulent exudate in the airways. In recovered lesions, 384 
whitish firm and thickened interlobular connective tissue formation (scars) can be observed 385 
(Thacker and Minion, 2012). 386 
Both clinical signs and macroscopic lesions are suggestive, but not exclusive, of M. 387 
hyopneumoniae infection. Other pathogens such as SIV or P. multocida should be considered 388 
within the most probably differential diagnoses (Sibila et al., 2009). Pasteurella multocida is 389 
considered a secondary pathogen, following infection with M. hyopneumoniae or another 390 
pathogen. Infections with P. multocida may cause catarrhal-purulent pneumonia, which is 391 
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grossly seen as cranioventral pulmonary consolidation (Register et al., 2012). At microscopic 392 
level, M. hyopneumoniae produces a well differentiated broncho-interstitial pneumonia. At 393 
early stages of infection, perivascular and peribronchiolar lymphoplasmacytic hyperplasia, 394 
pneumocyte type II hyperplasia and edema fluid in the alveolar spaces with presence of 395 
neutrophils, macrophages and plasma cells is observed (Blanchard et al., 1992). As disease 396 
progresses, these lesions are aggravated with an evident peribronchial and perivascular 397 
lymphoid follicles (Sibila et al., 2007), with and increased number of goblet cells and 398 
hyperplasia of submucosal glands (Thacker and Minion, 2012). 399 
Intensity of clinical signs and severity of lesions may depend on different factors, such as 400 
management, environmental conditions and M. hyopneumoniae strain. Information on the 401 
impact of strain variability may exert on lung lesions severity and clinical signs onset and 402 
duration is still not well defined. Whereas it has been reported that co-infection with more than 403 
one strain resulted in more severe lesions (Villarreal et al., 2009; Michiels et al., 2017), such 404 
potentiation was not observed in others (Charlebois et al., 2014). To date, the lack of a known 405 
virulence marker together with the coexistence of different strains at individual and farm levels 406 
(Nathues et al., 2011; Vranckx et al., 2011, 2012a; Pantoja et al., 2016), prevent knowing the 407 
impact of a particular strain on the severity of clinical signs and lung lesions.  408 
 409 
Socio-economic impact  410 
M. hyopneumoniae is a species-specific pathogen of suids. Therefore, it is not of zoonotic 411 
concern and no impact on public health is considered. However, infections with M. 412 
hyopneumoniae cause major economic losses to the pig industry, mainly because of reduced 413 
performance, uneven growth, increased number of days to reach slaughter weight, treatment 414 
and control costs, and increased mortality in case of complicated infections (Holst et al., 2015). 415 
Unfortunately, few updated information on the economic impact of EP is available, and existing 416 
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data have been mostly generated by assessing the relationship between evaluation of lung 417 
lesions at slaughterhouse with average daily weight gain (ADWG). Whereas a reduction of 6-418 
16% in the growth rate in finishing pigs was reported by some authors (Pointon et al., 1985, 419 
Rautiainen et al., 2000), no impact of lung lesions on ADWG at experimental (Escobar et al., 420 
2002; García-Morante et al., 2016) or natural (Scheidt et al., 1990; Straw et al., 1990) conditions 421 
was detected by other authors. The economic impact of M. hyopneumoniae subclinical infection 422 
has been inferred only once from the difference in ADWG (38 g/d) between seropositive and 423 
seronegative pigs from 18 different cohorts (Regula et al., 2000). The importance of subclinical 424 
infections should be further studied, especially in eradication programs. 425 
 426 
Diagnostics 427 
Clinical signs and lungs lesions can lead to a tentative diagnosis, but laboratory testing is 428 
necessary for a conclusive diagnosis. The use of remote systems for cough recording at the barn 429 
level and analysis appears to be a potential tool for early EP detection, although such systems 430 
have not been validated for M. hyopneumoniae infections in the field. 431 
Bacterial isolation remains a confirmatory method for pathogen detection; however the 432 
requirement to use specialized media, the high cost associated with the technique, the common 433 
overgrowth of other bacteria in the sample, and the low sensitivity of the method make 434 
significant detractors for this approach. Nevertheless, recent work from Cook et al. (2016) 435 
promises to aid controlling bacterial overgrowth with M. hyorhinis, and data from Ferrarini et 436 
al. (2016) may help with development of the highly needed media specifically suited for M. 437 
hyopneumoniae growth. Improving M. hyopneumoniae culture and isolation methods will help 438 
increasing strain collections, which can be used for research, diagnostics and vaccine 439 
development, and evaluation of antimicrobial sensitivity testing.  440 
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Tissue detection of M. hyopneumoniae can be accomplished with several techniques, including 441 
immunohistochemistry (IHC; Oppriesnig et al., 2004), in situ hybridization (ISH; Boye et al., 442 
2001) and PCR (Dubosson et al., 2005; Strait et al, 2008). In situ hybridization and ISH allow 443 
for detection of M. hyopneumoniae in the target tissue, however; this feature can be considered 444 
a limiting factor, as only small tissue sections can be evaluated. The application of PCR has 445 
allowed for a significant increase in detection of M. hyopneumoniae in multiple sample types 446 
and, nowadays, real-time PCR constitutes one of the most common methods for M. 447 
hyopneumoniae detection (Dubosson et al., 2005; Strait et al., 2008). Real-time PCR is 448 
characterized for its high specificity and sensitivity. Samples collected from the M. 449 
hyopneumoniae target tissue, such as bronchi and bronchioles in the lower respiratory tract, 450 
exhibit a higher sensitivity compared to samples obtained from the upper respiratory tract. In 451 
vivo sampling by means of tracheo-bronchial (Fablet et al., 2010) or laryngeal (Pieters et al., 452 
2017) swabs tested by real-time PCR appears to offer a high sensitivity, at least during the early 453 
stages of EP. Oral fluid samples tested by PCR have shown low sensitivity when compared to 454 
other sample types (Pieters et al., 2017), especially before clinical signs are evident. Further, 455 
Hernandez-Garcia et al. (2017) showed the lack of consistency of M. hyopneumoniae detection 456 
with the use of oral fluids, even after long periods of time post-infection. Ideally, an in vivo 457 
sample obtained from the bronchioles, and of easy collection, is envisioned by swine 458 
practitioners.  459 
Circulating antibodies (IgG) can be detected in pigs exposed to M. hyopneumoniae. Antibodies 460 
are developed several weeks after initial infection (Thacker and Minion, 2012), can be the result 461 
of maternal antibody absorption in piglets (Bandrick et al., 2008), or can be generated after 462 
vaccination (Maes et al., 2008). Antibodies against M. hyopneumoniae can be detected with 463 
ELISA tests regardless of origin, which complicates interpretation. Also, in the chronic phase 464 
of infection, antibodies against M. hyopneumoniae wane and are no longer detected. 465 
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Commercial ELISA kits are available for M. hyopneumoniae antibody detection, and although 466 
based on different antigens and ELISA platforms, they exhibit similar accuracy (Erlandson et 467 
al., 2005; Pieters et al., 2017) and are equally unable to differentiate pigs that have been 468 
vaccinated from those that have suffered from the disease. The use of several serological 469 
parameters to forecast lifetime pneumonia was assessed under natural and experimental 470 
conditions. The IgG2 OD-values at systemic levels showed the best correlation with M. 471 
hyopneumoniae associated lung lesions severity (García-Morante et al. 2017). Further research 472 
is warranted to improve ELISA assays, including discrimination between infected and 473 
vaccinated pigs, and providing higher specificity. 474 
 475 
Prevention and Control 476 
Management and biosecurity 477 
Avoiding the introduction of M. hyopneumoniae into negative farms is crucial in order to 478 
remain free from the infection. While M. hyopneumoniae-specific biosecurity measures have 479 
not been developed, the use of general strategies is recommended to maintain a M. 480 
hyopneumoniae-free status or to elude the introduction of new bacterial strains into herds. For 481 
example, the use of farm air filtration systems, usually in place to avoid infections with PRRSV, 482 
is becoming popular in sow farms in North America. However, the specific effect of air 483 
filtration systems on reduction of M. hyopneumoniae infections or the value in area control 484 
programs has not been evaluated.  485 
Introduction of M. hyopneumoniae via fomites does not appear to be a high risk for farms, and 486 
regular disinfection and decontamination systems are thought to be effective against this 487 
bacterium. Of special importance is the fact that M. hyopneumoniae survival outside of the host 488 
is limited, based on the pathogen dependence on the host environment. Nevertheless, data from 489 
Browne et al. (2017) suggests that M. hyopneumoniae can survive outside of host on certain 490 
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plastic surfaces and in dust for up to 8 days when temperatures are low (4°C). This information 491 
highlights the need to keep decontamination systems in place in order to avoid pathogen 492 
introduction.  493 
The highest risk for pathogen introduction to swine farms resides in incoming pigs and this is 494 
especially important for M. hyopneumoniae infections. The epidemiological features of this 495 
bacterium make it difficult for early detection and clinical presentation, although testing 496 
protocols, generally based on serological testing, are in place and are widely used to screen 497 
unvaccinated incoming pigs for M. hyopneumoniae infections. However, clinical outbreaks 498 
have been reported months after the suspected pathogen introduction, when control is far from 499 
being effective. Therefore, the development of diagnostic protocols aimed at early detection 500 
and surveillance, are of paramount importance.  501 
 502 
Therapeutics 503 
Antimicrobials active against M. hyopneumoniae include tetracyclines, 15- and 16-membered 504 
ring macrolides, lincosamides, pleuromutilins, fluoroquinolones, florfenicol, aminoglycosides 505 
and aminocyclitols (Hannan et al., 1997). M. hyopneumoniae is intrinsically resistant to 506 
antibiotics which interfere with the polymerization of cell wall precursors, such as beta-lactam 507 
antibiotics, and to polymyxins, 14-membered ring macrolides (such as oleandomycin and 508 
erythromycin), rifampin, trimethoprim and sulfonamides. Acquired resistance has been 509 
documented for tetracyclines, 16-membered ring macrolides (tylosin, tilmicosin), lincosamides 510 
(lincomycin) and fluoroquinolones (Stakenborg et al., 2005; Le Carrou et al., 2006; Vicca et 511 
al., 2007; Thongkamkoon et al., 2013; Tavío et al., 2014). The susceptibility to valnemulin and 512 
tiamulin may have decreased in the period 1997 (Hannan et al., 1997) to 2013 (Thongkamkoon 513 
et al., 2013; Tavío et al., 2014). However, taken together, acquired antimicrobial resistance does 514 
currently not seem to constitute a major problem for treatment of M. hyopneumoniae infections 515 
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(Klein et al., 2017), although the situation may be different for other bacteria complicating these 516 
infections. Finally, within a farm, strains with differences in antibiotic susceptibility may co-517 
exist (Thongkamkoon et al. 2013). 518 
Many different studies have shown the efficacy of various antimicrobials for the treatment and 519 
control of M. hyopneumoniae infections (reviewed by del Pozo Sacristán, 2014). For most 520 
antimicrobials tested, performance improved, and lung lesions as well as clinical signs 521 
decreased. Results of treating field cases of EP may be disappointing because the disease signs 522 
and the shedding of micro-organisms tend to reappear after cessation of the therapy. 523 
 524 
Vaccines 525 
Vaccination is widely applied worldwide to control M. hyopneumoniae infections. Commercial 526 
vaccines mostly consist of inactivated, adjuvanted whole-cell preparations that are administered 527 
intramuscularly (Maes et al. 2008). Table 1 gives an overview of different commercially 528 
available M. hyopneumoniae bacterin vaccines. Recently, an inactivated vaccine based on 529 
soluble antigens of M. hyopneumoniae is also commercially available (USA: Fostera PCV MH, 530 
Zoetis; in Europe: Suvaxyn Circo + MH RTU, Zoetis). It is a one-shot vaccine combined with 531 
PCV2 that can be administered to piglets from three weeks of age onwards. In addition, 532 
attenuated vaccines against M. hyopneumoniae have been licensed in China (Feng et al. 2013) 533 
and Mexico. The vaccine in Mexico is a thermosensitive mutant of M. hyopneumoniae 534 
(VaxSafe MHYO, Avimex).  535 
Vaccination reduces clinical signs and lung lesions and improves performance. Also, 536 
commercial vaccines reduce the number of organisms in the respiratory tract (Meyns et al., 537 
2006; Vranckx et al., 2012b) and decrease the infection level in a herd (Sibila et al., 2007). 538 
However, studies under experimental (Meyns et al., 2006) and field conditions (Pieters et al., 539 
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2010; Villarreal et al. 2011b) showed that vaccination conferred only a limited reduction of the 540 
transmission ratio of M. hyopneumoniae.  541 
The exact mechanisms of protection are not yet fully understood. Studies suggest that systemic 542 
cell-mediated immune responses are important for protection (Marchioro et al., 2013). Vranckx 543 
et al. (2012b) reported a lower infiltration of macrophages in the lung tissue in vaccinated 544 
animals upon infection with M. hyopneumoniae, indicating that vaccination modulates the 545 
immune response following infection. The importance of local mucosal antibodies remains 546 
unclear. The serum M. hyopneumoniae specific antibodies raised after vaccination are not suited 547 
to evaluate protective immunity (Djordjevic et al., 1997). 548 
Different vaccination strategies have been adopted, depending on the type of herd, production 549 
system and management practices, infection pattern and preferences of the pig producer. 550 
Vaccination of piglets, applied once or twice, is most commonly used. Single vaccination at 551 
either 7 or 21 days of age was efficacious in a pig herd with clinical respiratory disease during 552 
the second half of the fattening period (Del Pozo Sacristan et al., 2014). Recent experimental 553 
(Arsenakis et al. 2016) and field studies (Arsenakis et al. 2017a) showed that vaccinating piglets 554 
three days prior to weaning conferred slightly better results than vaccination at weaning, 555 
possibly because of less interference of weaning stress. 556 
Vaccination confers beneficial effects in most infected herds, but variable effects are obtained. 557 
This may be due to different factors such as improper vaccine storage conditions and 558 
administration, vaccination compliance, infection level, diversity of M. hyopneumoniae strains 559 
and co-infections. The influence of maternally derived antibodies on vaccine responses in 560 
piglets is not fully elucidated. Martelli et al. (2006) showed that passively acquired antibodies 561 
have little or no effect on either a vaccine induced priming or subsequent anamnestic response. 562 
Sibila et al. (2008) and Arsenakis et al. (2017b) showed that vaccination of sows at the end of 563 
gestation, resulted in a lower number of M. hyopneumoniae colonized piglets at weaning. 564 
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Breeding gilt vaccination is recommended in endemically infected herds to avoid 565 
destabilization of the breeding stock immunity (Bargen 2004). 566 
 567 
Constant effort is being directed towards the investigation of new vaccines that may offer a 568 
better protection against M. hyopneumoniae infections. In one study (Villarreal et al., 2009), 569 
infection with a low virulent M. hyopneumoniae isolate did not protect piglets against infection 570 
with a highly virulent M. hyopneumoniae isolate one month apart, suggesting that low virulent 571 
strains might not be suitable as such to be used as vaccines. Further research however is needed. 572 
Several studies have evaluated recombinant proteins of M. hyopneumoniae in various forms of 573 
administration and formulations. Table 2 summarizes the antigens, adjuvants, vectors and 574 
routes of immunization used in the studies on experimental M. hyopneumoniae vaccines. Most 575 
of the recombinant proteins were evaluated only in mice, and only a few of them were tested in 576 
challenge experiments in pigs. Some of the vaccines conferred protection, and may represent a 577 
promising tool for controlling M. hyopneumoniae infections in pigs. However, validation in 578 
pigs under experimental and practical circumstances is needed.  579 
 580 
Elimination 581 
Successful elimination of M. hyopneumoniae from swine herds has been reported over decades 582 
(reviewed by Holst et al., 2015) and several protocols have been developed. Besides 583 
depopulation and repopulation, initial efforts for disease elimination were based on the Swiss 584 
method (Zimmerman et al., 1989). This method includes partial depopulation (i.e. culling of all 585 
animals younger than 10 months of age) and whole herd medication, along with a two-week 586 
farrowing pause towards the end of the protocol. While this method has proven highly 587 
successful, its application in large herds is difficult. Thus, other protocols such as herd closure 588 
and medication, and whole herd medication, keeping young animals at the farms and piglet 589 
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production undisturbed, have been developed (Holst et al., 2015). The herd closure and 590 
medication strategy allows for the introduction of replacement gilts at the beginning of the 591 
process, relies on early exposure of the incoming females, and calls for no further introduction 592 
of susceptible animals for a period of at least 240 days, or when pathogen persistence has no 593 
longer been observed after initial infection (Pieters et al., 2009). In addition, quarterly mass 594 
vaccination is included as part of herd closure for disease elimination. On the other hand, the 595 
whole herd medication protocol is usually applied after clinical outbreaks of the disease, and 596 
does not require the culling of animals or pause in farrowing. However, the reported success of 597 
disease elimination is lower for this protocol compared to herd closure (Holst et al., 2015).  598 
Although elimination of M. hyopneumoniae is becoming increasingly common in the USA, 599 
several aspects of the protocols and the potential success could be questioned. For example, 600 
concerns exist on the likelihood to eliminate M. hyopneumoniae in high pig dense areas due to 601 
potential lateral infection of the herd, although this does not seem to occur frequently. Scientific 602 
information on lateral transmission of M. hyopneumoniae infections is largely missing, and 603 
previous evidence of pathogen airborne transmission can make a difficult case otherwise 604 
(Goodwin, 1985; Otake et al., 2010). Also, refinement of the elimination protocols is necessary 605 
for practicality and application in combination with other disease elimination programs. 606 
Nevertheless, elimination of M. hyopneumoniae from commercial herds, whether alone or in 607 
combination with the elimination of other pathogens, appears to be justified from the ethical 608 
and economical points of view (Yeske, 2016).  609 
  610 
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Conclusion 611 
M. hyopneumoniae is a very important pathogen that causes major losses to the pig industry. 612 
Research has focused on the epidemiology and transmission in different production systems, 613 
partly elucidated the very complex interaction of the pathogen with the respiratory tract, and 614 
has developed and tested many commercial and experimental vaccines. However, important 615 
knowledge gaps remain and, therefore, further research is needed to achieve a better control 616 
and possible elimination of the pathogen. The focus should be on better understanding of the 617 
virulence mechanisms and the interaction of the pathogen with the host and with other 618 
pathogens, and the development of vaccines that confer better protection and can be 619 
administered easily. Finally, research on how to successfully eliminate the pathogen from pig 620 
herds should also be stimulated. 621 
  622 
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Table 1: Most commonly used commercially available M. hyopneumoniae bacterin vaccines (2017) – Bacterin vaccines available in only one or 1109 
a few countries are not included the table. 1110 
Vaccine Antigen / Strain Adjuvant 
Route of 
administration 
Age of administration 
(days) 
Boosts needed 
after …weeks 
Hyogen (Ceva) Ceva strain BA 2940-99 Imuvant (W/O J5 LPS) IM ≥21 - 
HYORESP (Merial) NI a Aluminium hydroxide IM ≥5 3-4 
INGELVAC MYCOFLEX 
(Boehringer Ingelheim) 
J strain isolate  
B-3745 
Impran (water-in-oil adjuvant  
emulsion) 
IM ≥21 - 
M+Pac (Intervet Int.) b NI a 
Mineral oil and 
Aluminium hydroxide 
IM ≥7 3-4 
MYPRAVAC SUIS (Hipra Lab) J strain Levamisole and carbomer IM ≥7-10 3 
PORCILIS M. HYO (Intervet) Strain 11 dl--tocopherol acetate IM ≥7 3 
Porcilis PCV M. HYO 
(MSD-Intervet Int) c 
J Strain 
Mineral oil and 
Aluminium hydroxide 
IM ≥21 - 
Porcilis MHYO ID Once 
(MSD-Intervet Int.) 
Strain 11 
Paraffin oil and 
dl-α-tocoferylacetaat 
ID ≥14 - 
STELLAMUNE 
MYCOPLASMA (Eli Lilly) 
NL 1042 Mineral oil and lecithin IM ≥3 2-4 
STELLAMUNE ONE (Eli Lilly) NL 1042 
Amphigen Base, and Drakeol 5 
(mineral oil) 
IM ≥3 - 
SUVAXYN M.HYO d (Zoetis) P-5722-3 Carbopol IM ≥7 2 
SUVAXYN MH-ONE e (Zoetis) P-5722-3 Carbopol and squalane IM ≥7 - 
SUVAXYN M.HYO – 
PARASUIS f (Zoetis) 
P-5722-3 Carbopol and squalane IM ≥7 2 
39 
 
a No information available 1111 
b Vaccination scheme when one ml is used for each administration. No boost vaccination needed if a 2 ml dose is used the first time. 1112 
c Combination vaccine with  Porcine Circovirus type 2 1113 
d Named Suvaxyn RespiFend MH in USA 1114 
e Same name is used in the USA, but Amphigen is used as adjuvant in the USA, and vaccine can be administered from day one of age onwards 1115 
f Combination vaccine with Haemophilus parasuis - Named Suvaxyn RespiFend MH HPS in USA 1116 
  1117 
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 1118 
Table 2: Overview of experimental vaccines against M. hyopneumoniae 1119 
 1120 
Antigen Vacinne type Vector/Adjuvant Species Route 
Challenge 
infection Reference 
P97 Recombinant Subunit Complete Freund’s adjuvant pig 
IM** 
 
yes King et al. 1997 
NrdF (R2) Recombinant Vector Salmonella Typhimurium 
aroA SL3261 
mice 
Oral 
 
no Fagan et al. 1997 
P97 (R1) Recombinant Vector Pseudomonas aeroginosa exotoxin A 
mice and 
pig 
SC*** 
and IM 
no Chen et al. 2001 
NrdF (R2) Recombinant Vector Salmonella Typhimurium 
aroA SL3261 pig
 
Oral 
 
yes Fagan et al. 2001 
Strain PRIT-5 Inactivated whole cell Spray dried microspheres pig 
Oral 
 
yes Lin et al. 2003 
P42 
 
DNA pcDNA3 mice IM no Chen et al. 2003 
P97 (R1R2) Recombinant Vector Erysipelothrix rhusiopathiae 
YS-1 
mice and 
pig 
SC and 
IN**** 
 
no 
Shimoji et al. 2003 
P97 (R1) Recombinant Vector 
Salmonella Typhimurium 
aroA CS332 
mice 
Oral 
 
no Chen et al. 2006a 
NrdF (R2) Recombinant Vector Salmonella Typhimurium 
aroA CS332 
mice 
Oral 
 
no Chen et al. 2006b 
P97 (R1) Recombinant Subunit LTB mice IM and 
IN 
no Conceição et al. 2006 
P97 (R1) Recombinant Vector Adenovirus mice IM and 
IN 
no Okamba et al. 2007 
P97 (R1R2) Recombinant Vector Erysipelothrix rhusiopathiae 
Koganei 
pig 
Oral 
 
yes Ogawa et al. 2009 
P97 (R1) Recombinant Vector Adenovirus pig 
IN 
 
yes Okamba et al. 2010 
P36 Recombinant Vector 
Actinobacillus pleuropneumoniae 
SLW36 mice
 
IM 
 
no Zou et al. 2011 
34* Recombinant Subunit Aluminun mice 
IM 
 
no Simionatto et al. 2012 
41 
 
P37, P42,  
P46, P95 
Recombinant Subunit  
and DNA 
Aluminium and 
pcDNA3 mice 
IM 
 
no Galli et al. 2012 
P97 (R1,R2) 
Recombinant chimeric 
Subunit 
Heat-labile enterotoxin E. coli (LTB) 
and Montanide IMS 
mice IM no Barate et al. 2014 
P46, 
HSP70,MnuA 
Recombinant Subunit 
and DNA 
Complete Freund’s adjuvant mice Intra-peritoneal no Virginio et al. 2014 
P97, P42, 
NrdF 
Recombinant chimeric 
Subunit 
Heat-labile enterotoxin E. coli (LTB) pig IM and IN no Marchioro et al. 2014 
HSP70 Recombinant Subunit 
Mesoporous silica nanoparticles SBa-
15 and SBa-16, Aluminium 
mice Intra-peritoneal no Virginio et al. 2017 
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